(PDF) Durvalumab Extends OS in NSCLC - Cancer Discovery

Durvalumab Extends OS in NSCLC

Cancer Discovery - United States

doi 10.1158/2159-8290.cd-nb2018-135

Full Text

Abstract

Available in full text

Categories

Date

October 16, 2018

Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III

Respiratory Medicine

English

Refractory Severe Esophagitis During Durvalumab Therapy in a Patient With Locally Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Journal of Thoracic Oncology

Respiratory Medicine

English

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control in ATLANTIC

Journal of Thoracic Oncology

Respiratory Medicine

English

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology

Respiratory Medicine

English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-70 Efficacy and Safety of Second- Or Third-Line Nab-Paclitaxel + Durvalumab in Patients With Advanced NSCLC (ABOUND.2L+)

Journal of Thoracic Oncology

Respiratory Medicine

English